bioihbjkbjnl/mcl2 huggingface dataset:
-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.
Condition: Type 2 Diabetes
Study type: Interventional

Summary: 
      The purpose of this study is to evaluate the impact of different ligands of GPR 119 (a G
      protein-coupled receptor in the intestine) on the secretion of the incretin hormones, GLP-1
      and GIP.
    

Detailed description: 
      We have found a new ligand for the GPR 119 receptor. This study evaluate the impact of this
      ligand on the incretion hormone responses, beta cell function and gall bladder function in
      healthy young men.
    

Intervention name(s): GPR 119 agonist, 2-oleyl glycerol; Oleic acid; Vehicle
Intervention type(s): Dietary Supplement; Dietary Supplement; Dietary Supplement
Intervention description(s): Emulgation, 50 ml. containing 2g 2OG; Emulgation, 50 ml. containing 1.54g of oleic acid; Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
Intervention MeSH terms: Glycerol
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Single (Participant)
Primary purpose: Basic Science
Keywords: GPR 119; GLP-1 secretion; 2-oleoyl-glycerol; Dietary supplementation
Evaluation of a New Sonoclot Device for Heparin Management in Cardiac Surgery
Condition: Diagnostic Techniques and Procedures; Cardiac Surgical Procedure
Study type: Interventional

Summary: 
      The SONOCLOT Analyzer (S1; Sienco, Inc. Boulder, CO USA, Model DP-2951) is used to perform
      kaolin-based activated clotting time as routine monitor of heparin therapy in patients
      undergoing cardiac operations. In addition, the device allows the assessment of the patient's
      coagulation status by a glass-bead activated test. Recently, a new SONOCLOT analyzer (S2) has
      been developed. As part of the routine management using S1, tests are also performed on S2.
      Results are entered into the cardiac surgery data base of all cardiac surgery patients and
      analyzed.
    

Detailed description: 
      The SONOCLOT Analyzer (S1; Sienco, Inc. Boulder, CO USA, Model DP-2951) is used to routinely
      perform kaolin-based activated clotting time (kACT) as monitor of heparin therapy in patients
      undergoing cardiac operations on cardiopulmonary bypass.

      Apart from kACT, the device allows the assessment of the patient's coagulation status by a
      glass-bead activated test (gbACT+, depicting also clot rate = CR and platelet function = PF).
      Recently, a new SONOCLOT analyzer (S2) has been developed. Although the S2 shares the
      technical fundamentals with the S1, the redesign of the device may result in performance
      changes of kACT and gbACT.

      Routine management in cardiac surgery patients is guided using S1 and addition, tests are run
      on S2. Data are entered into the the cardiac surgery data base and S1 and S2 performance is
      compared by Bland-Altman analysis and % error calculation in order to establish new reference
      values.
    

Intervention name(s): Sonoclot Analyzer
Intervention type(s): Device
Intervention description(s): Blood coagulation test during cardiac surgery: Measurement of activated clotting time during cardiac surgery by Sonoclot Analyzer
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
Keywords: Activated clotting time; Sonoclot
Correlation Between Various Adipokines and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG) (18FDG-PET)
Condition: Atherosclerosis
MeSH terms: Atherosclerosis; Inflammation
Study type: Observational

Summary: 
      The inflammatory state and composition of atherosclerotic plaques are considered the main
      contributing factors responsible for acute cardiovascular events, rather than the degree of
      stenosis. Recently, positron emission tomography (PET) with 18F-fluoro-deoxyglucose (FDG) has
      been suggested as a promising novel imaging technique to identify the inflammatory state of
      atherosclerotic plaque. Recently, a few clinical studies showed that circulating A-FABP level
      had a close relation with the development of atherosclerosis in human. Therefore, in the
      present study, the investigators examined the relationship between circulating A-FABP and
      vascular inflammation of carotid arteries measured using FDG-PET in healthy male subjects.
    


Intervention name(s): Cross sectional study
Intervention type(s): Other
Intervention description(s): This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
Observational model: Case-Only
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        Healthy male participats who underwent a medical health check in the health promotion
        center in Korea Guro University
      
Biospecimen description: 
      whole blood, plasma, serum
    
Keywords: atherosclerosis; vascular inflammation; adipocyte fatty acid binding protein; adiponectin; leptin; 18FDG-PET
Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548
Condition: Healthy Volunteers
Study type: Interventional
Phase: Phase 1

Summary: 
      The primary purpose of this study is to assess the single-dose bioavailability of AKB-6548
      with ferrous sulfate relative to AKB-6548 in healthy volunteers.
    


Intervention name(s): AKB-6548; Ferrous Sulfate
Intervention type(s): Drug; Drug
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Other
Keywords: Pharmacokinetics; Anemia; Chronic kidney disease; CKD; Chronic renal insufficiency; Renal impairment; Ferrous sulfate; Iron; Drug-drug interaction; End stage renal disease; Dialysis; Erythropoietin; Oral anemia treatment; Hypoxia-induciable factor; HIF; Hypoxia-induciable factor prolyl-hydroxylase inhibitor; HIF-PHI
Celecoxib Versus Hyoscine Butyl-bromide in Reducing Pain Associated With IUD.
Condition: IUD Insertion Pain
Study type: Interventional

Summary: 
      Many oral analgesic drugs such as the nonsteroidal anti-inflammatory drug (NSAID) are used to
      relieve pain from gynaecological procedures and dysmenorrhea. Hyoscine-N-butyl bromide, an
      antispasmodic drug is commonly used for relief of smooth muscle spasms and can be used to
      alleviate genito-urinary spasm. Some studies reported hyoscine couldn't relieve pain in minor
      gynaecological procedures. So the efficacy of Hyoscine-N-butyl bromide use is still
      controversial, and no previous studies investigated its effectiveness for pain relief in IUD
      insertion procedure.
    

Detailed description: 
      The study objective is to compare the effectiveness and side effects of oral Celecoxib 200mg
      versus oral hyoscine butyl bromide 10 mg in reducing pain associated with IUD insertion. the
      study is an attempt to find the most effective drug with the least possible side effects to
      be used before IUD insertion.
    

Intervention name(s): hyoscine butyl bromide; Celecoxib 200mg; Placebo Oral Tablet
Intervention type(s): Drug; Drug; Drug
Intervention description(s): intake of 10 mg hyoscine butyl bromide (buscopan) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion; Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide; a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib.
Intervention MeSH terms: Celecoxib; Scopolamine; Bromides; Butylscopolammonium Bromide
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Prevention
Does High Intraoperative Inspired Oxygen Reduce Postoperative Arterial Oxygen Saturation?
Condition: Atelectasis
MeSH terms: Pulmonary Atelectasis
Study type: Interventional
Phase: Phase 2/Phase 3

Summary: 
      The purpose of this study is to determine whether breathing high levels of oxygen during
      surgery affects oxygen levels after surgery. The second purpose of this study is to determine
      whether giving positive end expiratory pressure PEEP and high oxygen together affects
      patients oxygen levels after surgery.
    

Detailed description: 
      This is a randomized, controlled, blinded trial in patients undergoing non-abdominal surgery
      of the effect of intraoperative increased inspired oxygen used (FiO2>0.9 vs. FiO2 = 0.3) on
      non-invasive oxygen saturation (pulse oximetry, SpO2) and amount of required supplemental
      oxygen in the post-anesthesia care unit (PACU); arterial oxygen partial pressure (PaO2) after
      45 minutes in the PACU; room air SpO2 24 hours after surgery, and amount of supplemental
      oxygen required 24 hours after surgery. The purpose of the study is to determine whether
      absorption atelectasis induced by use of inspired oxygen concentrations in excess of 90%
      leads to a higher risk of hypoxemia, as evidenced by room air oxygen values and the need for
      supplemental oxygen. The objective of this study is to determine whether high inspired oxygen
      (>0.8), which has been demonstrated to reduce the risk of surgical site infection in patients
      undergoing colon surgery and other major surgical procedures has side effects that limit its
      use to prevent infection in lower risk operations.

      There are four groups of intraoperative ventilation management in this study. Fi02 0.3 plus
      PEEP, Fi02 0.3 without PEEP, Fi02 greater than 0.9 plus PEEP 3 to 5 cm of water, Fi02 greater
      than 0.9 without PEEP.
    

Intervention name(s): FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3 -5 cm water; FiO2 0.3 without PEEP; FiO2 >0.9 with 3-5 cm water PEEP; FiO2 >0.9 without PEEP
Intervention type(s): Other; Other; Other; Other
Intervention description(s): FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3-5 cm water; FiO2 0.3 without PEEP; FiO2 >0.9 with 3-5 cm water PEEP; FiO2 >0.9 without PEEP
Other intervention name(s): O2; Dioxygen; Sats; Oxygen Saturation; Pulmonary ventilation rate; Ventilation rate; Breathing rates; positive end expiratory pressure; O2; Dioxygen; Sats; Oxygen Saturation; Pulmonary ventilation rate; Ventilation rate; Breathing rates; O2; Dioxygen; Sats; Oxygen Saturation; Pulmonary ventilation rate; Ventilation rate; Breathing rates; positive end expiratory pressure; O2; Dioxygen; Sats; Oxygen Saturation; Pulmonary ventilation rate; Ventilation rate; Breathing rates
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Diagnostic
Keywords: atelectasis; oxygen; saturation
Cesarean Rate in Parturients Without Neuraxial Analgesia
Condition: Labor
Study type: Interventional

Summary: 
      Currently, it is certain that neuraxial analgesia in early stage of labor and delivery dose
      not increase the risk of Cesarean section. However, given ethical reasons, whether such a
      medical procedure could increase the Cesarean rate compared with those who did not received
      neuraxial analgesia or not is yet to be known. It is difficult to perform such a study in
      occidental countries because they have a higher rate of labor analgesia. On the contrary, the
      rate of labor analgesia in China is up to date only 1%, so it can be done easily. The
      investigators hypothesized that no neuraxial analgesia itself were a risk factor to Cesarean
      section. Therefore, the investigators design this study to compared the effect of neuraxial
      analgesia on the rate of Cesarean delivery with those who did not received neuraxial
      analgesia.
    


Intervention name(s): Neuraxial analgesia; Non-neuraxial analgesia
Intervention type(s): Procedure; Procedure
Intervention description(s): Neuraxial analgesia will be given at any time if the parturient requested analgesia; No neuraxial analgesia will be given to those who will not want to an analgesia
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Epidural analgesia; Latent analgesia; Active analgesia; Cesarean section
To Comapre The Effectiveness of Two Lasers in The Treamment of Unwanted Hair
Condition: Hirsuitism
MeSH terms: Hirsutism
Study type: Interventional

Summary: 
      A total of 60 female patients (30 patients in each group) with unwanted facial hair diagnosed
      by a consultant dermatologist were included in this study. In Group A patients were subjected
      to intense pulse light therapy while patients in Group B were subjected to diode laser for
      three sessions one month apart. Effectiveness in both groups was ascertained in terms of hair
      reduction, less adverse effects, side effects and patients' satisfactory response at the end
      of final session.
    


Intervention name(s): IPL; Diode
Intervention type(s): Procedure; Procedure
Intervention description(s): Patients in Group A received intense pulse light (IPL) frequency of 690. A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by patients' were recorded.; patients in Group B received diode laser treatment system. Diode laser was employed using triple wavelength (1064, 810 and 755 mm). A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by the patients were recorded.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Other
Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus
Condition: Type 2 Diabetes Mellitus
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 1

Summary: 
      Investigate the acute effect of the steviol glycoside, rebaudioside A, on the glucose
      excursion during an oral glucose tolerance test in 30 patients with type 2 diabetes mellitus.
    

Detailed description: 
      Eligible individuals with type 2 diabetes mellitus will be invited for four study visits.
      During the first and third study visit, rebaudioside A or the placebo will be administered.
      During the second and fourth study visit, an oral glucose tolerance test (OGTT) will be
      executed to measure the response of administration of rebaudioside A versus placebo on the
      glucose homeostasis. The area under the curve blood glucose values during the first two hours
      of the OGTT will be compared for both conditions.
    

Intervention name(s): Rebaudioside A; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Rebaudioside A 3g; Empty capsules
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Therapeutic Issues for Autism
Condition: Autism Spectrum Disorder
MeSH terms: Autistic Disorder; Autism Spectrum Disorder
Study type: Interventional
Phase: Phase 2

Summary: 
      This study aimed to show the effects of hyperbaric oxygen therapy and/or Risperidone in
      improving symptoms of autism
    

Detailed description: 
      Autism spectrum disorders (ASDs) are clinical disorders with multiple developmental
      disabilities in skills associated with overall behavior and communication. The term (ASD)
      includes Autistic Disorder (AD), Pervasive Developmental Disorder-Not Otherwise Specified
      (PDD-NOS), and Asperger's Disorder .

      Hyperbaric oxygen therapy (HBOT) is a treatment in which patients inside a hyperbaric chamber
      breathe a concentrated oxygen pressurized more than sea level (1 atmosphere absolute) .

      It was obvious that autistic children may have some benefits of HBOT by increasing in
      cerebral perfusion during treatment. Inhalation of more pressurized oxygen might elevate
      partial pressure of oxygen in the arterial blood, and increased oxygen that reaches the brain
      . Another mechanism of action of HBOT that it might have anti-inflammatory properties by
      reduction of pro-inflammatory cytokines, interleukins 1 and 6, interferon-γ, and tumor
      necrosis factor-α. Furthermore, HBOT might enhance mitochondrial dysfunction, and upregulate
      the antioxidant enzymes production.

      Risperidone is a second generation antipsychotic, approved by the Food and Drug
      Administration (FDA) for treatment of autism-related irritability. Its approved in 2006 only
      for children not less than 5 years old . This trial aimed to study the effects of hyperbaric
      oxygen therapy and/or Risperidone in management symptoms of autism.
    

Intervention name(s): Risperidone; hyperbaric oxygen therapy; Non specific Multivitamin
Intervention type(s): Drug; Device; Drug
Intervention description(s): It is antipsychotic drug used by dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more for 8 months.; Sessions were done at pressure 1.5 ATA (atmosphere absolute) with 100% oxygen concentration, each lasting for one hour either in multiplace chamber or in monoplace chamber.; control group received non specific multivitamins as placebo for 8 months.
Other intervention name(s): Resperidal
Intervention MeSH terms: Risperidone
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Children were divided into four groups.Twenty autistic children in each group. They followed up for 2 years.
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: Autism; Childhood Autism Rating Scale; Hyperbaric oxygen; Risperidone
Time to Accurate Heart Rate on Neonatal Outcomes
Condition: Premature Infant; Extremely Low Birth Weight; Extreme Prematurity
MeSH terms: Birth Weight
Study type: Interventional

Summary: 
      The goal of this trial is to compare the time to first heart rate displayed for iRes Warmer
      with ResusView and using iRes Warmer without ResusView when used in the resuscitation (e.g.
      Cardiopulmonary resuscitation or breathing assistance) of premature newborns (23 to 32+6
      weeks gestation).
    

Detailed description: 
      This is a prospective interventional randomized control trial. Infants born between 23+0 and
      32+6 estimated gestational age will be randomized using a computer generate allocation
      sequence stratified by gestational age. Randomization cards will be placed in opaque
      envelopes. For the intervention group, the care team will use the Panda iRes Warmer with
      ResusView Bed during resuscitation interventions in the first 10 minutes of life. During use
      of the iRes-warmer, standard nursing care of an infant on a radiant warmer will be followed.
      Participants assigned to the control group will receive interventions using the same model
      Panda bed without ResusView. There is no minimum time for monitoring, and the maximum time
      depends on clinical determination for use of heart rate feature for each resuscitation event.
      Data including the infant's gestational age, Electrocardiogram lead type and activities that
      occurred during resuscitation will be recorded for the first 10 minutes of life.
    

Intervention name(s): iRes Warmer with ResusView; iRes Warmer without ResusView
Intervention type(s): Device; Other
Intervention description(s): Rapid heart rate display utilizing optimized ECG algorithm in iRes Warmer in babies delivered between 23+0 and 32+6 weeks estimated gestational age; Electrocardiogram monitoring using external ECG monitor in babies delivered between 23+0 and 32+6 weeks estimated gestational age
Other intervention name(s): Panda Bed with ECG Feature; Standard of Care
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Health Services Research
Keywords: electrocardiogram; Neonatal Resuscitation; resuscitation of premature infants
Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
Condition: Asthma
MeSH terms: Asthma
Study type: Interventional

Summary: 
      This is a pivotal, 12-month, randomized, sham controlled, parallel group, multicenter, double
      blind study with an allocation ratio of 1:1. The study population is children between the
      ages 6 to 17 years, with mild to moderate persistent asthma. The purpose of the study is to
      determine whether the CREON2000A, an environmental control device, will decrease asthma
      severity, as measured by the Composite Asthma Severity Index (CASI), in children with mild to
      moderate persistent allergic asthma over a twelve month period.
    

Detailed description: 
      The pilot study (Protocol #PA-01-052; Health Effects of CREON2000 in Asthmatic Children. IB
      ID# GI 1001) offered preliminary evidence that the CREON2000A system may be beneficial in
      asthma. This study is a follow-up, using children, aged 6 to 17 with mild to moderate
      persistent asthma, as the subjects of the study. Children are usually treated with fewer
      controller medications and have fewer confounding co-morbidities making it more likely to
      detect a therapeutic benefit from an environmental intervention. The study will involve 4
      study site visits, 2 home visits, and 7 phone calls. Adjustment of asthma therapy by the site
      clinician will occur at baseline (Visit 1) and at each follow-up office visit after Visit 1
      using a modified algorithm based on the National Asthma Education and Prevention Program
      Expert Panel Report 3 (NAEPP EPR3) guidelines. Enrollment will be over 18 months. The study
      duration for each subject will be 12 months.
    

Intervention name(s): CREON2000A
Intervention type(s): Device
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: asthma environment